linjc16/ctgov huggingface dataset:
Evaluation of Osteoporosis Support After a Severe Osteoporotic Fracture in Women Over 50 Years in University Hospital

Study Overview
=================
Brief Summary
-----------------
Evaluate the support of osteoporosis in women over 50 years with severe osteoporotic fractures (hip, vertebral, rib, Humeral, pelvic fractures) in the Nîmes University Hospital taking prediction of treatment of osteoporosis as criterion.

Conditions
-----------------
Osteoporosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients over 50 years (> 50 years) with severe osteoporotic fractures (hip, vertebral, rib, Humeral, pelvic fractures) hospitalized in the Nîmes University Hospital Exclusion Criteria: patient under 50 years Non osteoporotic fractures

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Is the treatment of osteoporosis scheduled according to the hospital report? yes/no |  | 1 year |
National Survey on GERD Patients (Adults and Children)

Study Overview
=================
Brief Summary
-----------------
To describe GERD digestive expression according to ages: - children (from 0 to 23 months) and (24 months and more)- adults (from 18 to 29 years old), (from 30 to 39 years old), (from 40 to 49 years old), (from 50 to 59 years old), (more than 60 years old)

Official Title
-----------------
National Survey on GERD Patients (Adults and Children)

Conditions
-----------------
GERD (Gastroesophageal Reflux Disease)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults : - Male or female > or = 18 years old - With at least one GERD typical clinical sign (pyrosis and / or acid regurgitations).- Not receiving any GERD treatment within the 3 previous months. Children :- Male or female < 18 years old - With GERD digestive clinical signs during the consultation (receiving treatment or not)- Whose parents or legal guardian gave oral approval to the child participation in the survey. Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>For GP : the first 3 consecutive adult patients and the first children seen during the GP's visit with a diagnosis of GERD. | |
| 2<br>For Paediatrics : the first 2 consecutive children seen during the Paediatric's visit with a diagnosis of GERD. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To describe GERD digestive expression according to ages: - children (from 0-23 months) and (24 months and more)- adults (from 18-29 years old), (from 30-39 years old), (from 40-49 years old), (from 50-59 years old), (more than 60 years old) |  | once | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
GERD digestive expression, ages
Repetitive Transcranial Magnetic Stimulation(rTMS) in the Treatment of Depression

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to investigate the antidepressant efficacy of rTMS, and to assess cortical metabolism before and after rTMS sessions in patients with major depression. We also aimed to investigate differences between the responders and nonresponders to rTMS and what would predict clinical response to rTMS.

Detailed Description
-----------------
The specific aims of this study is to: (1) evaluate the antidepressant efficacy of rTMS on major depression; (2) evaluate the effects of rTMS on cognitive function in depressive patients; (3) assess the effects of rTMS on cerebral glucose metabolism in depressive patients as measured by 18FDG PET; (4) investigate the differences of the regional cerebral glucose uptake changes during rTMS between responders and nonresponders to rTMS.

Official Title
-----------------
Repetitive Transcranial Magnetic Stimulation(rTMS) in the Treatment of Depression : Effect of TMS on Depression, Cognitive Function, and Regional Cerebral Glucose Metabolism

Conditions
-----------------
Major Depressive Disorder

Intervention / Treatment
-----------------
* Device: repetitive Transcranial Magnetic Stimulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Twenty patients fulfilling the diagnostic criteria of major depression according to DSM IV will be enrolled in the study. Antidepressant medication will be maintained throughout the study period. Exclusion Criteria: Exclusion criteria are current neurological or other psychiatric disorders, as well as a history of epileptic seizures, substantial brain damage or neurosurgical operation, according to established safety criteria. To exclude the effect of drug changes on post-rTMS cerebral glucose metabolism, the combinations and dosage of pre-rTMS antidepressant drugs will remain unchanged until the post-rTMS 18FDG PET is done.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| repetitive Transcranial Magnetic Stimulation<br>repetitive Transcranial Magnetic Stimulation is a depressive patient group treated with rTMS | Device: repetitive Transcranial Magnetic Stimulation<br>* 10 times repetitive TMS, high frequency<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hamilton depression rating scale (HAM-D 17) | measuring instrument of severity of depressive symptoms | baseline, 1, 2, and 4 weeks after TMS | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
repetitive Transcranial Magnetic Stimulation, Major Depressive Disorder
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Sclerosing Cholangitis.

Official Title
-----------------
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis

Conditions
-----------------
Primary Sclerosing Cholangitis

Intervention / Treatment
-----------------
* Biological: NGM282
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of PSC Exclusion Criteria: Clinically significant acute or chronic liver disease of an etiology other than PSC Secondary or IgG4 related sclerosing cholangitis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NGM282 Dose 1<br>NGM282 Dose 1 | Biological: NGM282<br> <br> |
| Experimental: NGM282 Dose 2<br>NGM282 Dose 2 | Biological: NGM282<br> <br> |
| Active Comparator: Placebo<br>Placebo | Other: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The mean and percent change in ALP from Baseline to Week 12 |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The mean and percent change in ALT from Baseline to Week 12 |  | 12 weeks |
New Therapeutic System of Unruptured Intracranial Aneurysms Based on Big Data From Chinese Population

Study Overview
=================
Brief Summary
-----------------
This is a prospective, multicenter, observational study, aiming at comparing the Safety and effectiveness among the different surgical treatment of unruptured intracranial aneurysms in China, so as to improve the diagnosis and treatment of unruptured intracranial aneurysms.

Official Title
-----------------
New Therapeutic System of Unruptured Intracranial Aneurysms Based on Big Data From Chinese Population

Conditions
-----------------
Unruptured Cerebral Aneurysm, Treatment Strategy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients diagnosed with unruptured intracranial saccular aneurysm on CTA, MRA or DSA. patients willing to participate in this clinical trial and attach to regular follow up. Exclusion Criteria: intracranial aneurysm correlating to AVM. intracranial non-saccular aneurysm. the rupture or unrpture of the aneurysm confirmed on CTA、MRA or DSA. patients unwilling to participate in this clinical trial and attach to regular follow up.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality and disability | the rate of death and disable | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| recurrence rate |  | 1 month, 6 months and 1 year after surgery; | 
| progression of disease | enlarge or ruptured of the aneurysm | 1 month, 6 months and 1 year after conservative treatment； |
Admixture Mapping of Ethnic and Racial Insulin Complex Outcomes

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to investigate the effect of genetic and environmental parameters on racial/ethnic differences in aspects of insulin secretion and action. The genetic component will be modeled by estimating the degree of European genetic admixture (ADM) obtained from approximately 50 ancestry informative markers (AIMs). The environmental components will be modeled by measuring energy intake (food intake), energy expenditure (physical activity) and socioeconomic status.

Official Title
-----------------
Admixture Mapping of Ethnic and Racial Insulin Complex Outcomes

Conditions
-----------------
Healthy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: African American, European American, or Hispanic American, aged 7-12, healthy, weight is equal to or greater than 25 Kg Exclusion Criteria: Type 1 or 2 diabetes, polycystic ovary disease, disturbances in glucose or lipid metabolism disturbances Use of medication known to affect body composition or physical activity, diagnosis of genetic disorders known to affect body composition or fat distribution Use of tobacco, alcohol consumption in excess of 400 g per week Menstruated for more than a year prior to the recruitment; OR A medical history that counter-indicates inclusion of the study

Ages Eligible for Study
-----------------
Minimum Age: 7 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A, Observational<br>Healthy European American, African American, and Hispanic American children aged 7-12 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To test the role of European genetic admixture on measures of insulin action and response in a multiethnic group of prepubertal children. |  | 5 years | 
| To investigate whether the impact of energy intake, energy expenditure and socioeconomic status on proxy measures of insulin sensitivity and/or action differ as a function of European ADM in prepubertal children |  | 5 years | 
| To test phenotype-genotype associations between each one of the AIMs and measures of FI, SI and AIRg after adjusting for body composition in a sample of AA, HA and EA prepubertal children. |  | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
race/ethnicity, insulin senistivity, genetic admixture, type 2 diabetes, obesity, body composition, Insulin dynamics, Racial/ethnic differences
Symptom Based Treatment of Neuropathic Pain

Study Overview
=================
Brief Summary
-----------------
1. Neuropathic pain in spinal cord injured patients Inclusion criteria pain intensity, visual analogue scale > 3 a LANSS (Leeds assessment of neuropathic symptoms and signs) score of 12 and above aged ≥20 Method Stop pain medications Test oxcarbazepine (150mg twice daily) and pregabalin (150mg twice daily) Check pain intensity (VAS score) with Baron's classification

Detailed Description
-----------------
In the present study, pharmacologic treatment included pregabalin and oxcarbazepine. Stop medications such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), tramadol and anti-spastic drugs (baclofen, tizanidine) and other medications known to have effect on pain and the central nervous system prior to the study for at least 3 days. Pain intensity (VAS score) 4 spontaneous characters electric burning pricking numbness evoked pain allodynia heat hyperalgesia pressure hyperalgesia Location of neuropathic pain neuropathic pain at level of spinal cord injury neuropathic pain below level of spinal cord injury 2. Side effects

Official Title
-----------------
Symptom-Based Treatment for Neuropathic Pain in Spinal Cord Injured Patients, Randomized Clinical Trial

Conditions
-----------------
Neuralgia, Spinal Cord Injury

Intervention / Treatment
-----------------
* Drug: Pregabalin and Oxcarbazepine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged than 20 years Neuropathic pain symptoms : LANSS (Leeds assessment of neuropathic symptoms and signs) score of 12 and above Visual analogue scale score of 3 and above Exclusion Criteria: No pregnancy systemic disease psychiatric disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pregabalin and Oxcarbazpepine<br>Pregabalin and Oxcarbazepine | Drug: Pregabalin and Oxcarbazepine<br>* Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day. Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice.<br>* Other names: Lyrica and Oxcarb;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptom based treatment of neuropathic pain | Pain intensity using Visual analogue scale (0 100) | 2 week later | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Neuralgia, Spinal cord, Oxcarbazepine, Pregabalin, Drug therapy, Algorithms
Skin to Adductor Canal Distance in Various Positions

Study Overview
=================
Brief Summary
-----------------
To control pain after total knee replacement surgery a catheter (tubing) is sometimes inserted into an anatomic space containing nerves that provide sensation to parts of the knee. This space is called the adductor canal. The catheters often stop working before we remove them for unclear reasons. The investigators think this is because the catheters become dislodged from where it was meant to be. This could be due to repeated movements of the catheter tip brought on by patients contracting their leg muscles when they ambulate or perform physio. The investigators want to confirm this by measuring the distance from a fixed spot on the patient's thigh to the adductor canal using an ultrasound machine. The leg will be measured in various positions to simulate muscle movements. A significant change in the distance could possibly contribute to catheter dislodgement and result in catheter failure.

Official Title
-----------------
The Impact of Leg Movement on the Skin to Adductor Canal Distance: a Potential Cause for Catheter Displacement?

Conditions
-----------------
Knee Arthritis

Intervention / Treatment
-----------------
* Other: Measurements Using Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over or equal to the age of 18 years old who can understand the study protocol and are able to give consent Patients must be undergoing a primary total knee arthroplasty with neuraxial anaesthesia Exclusion Criteria: Patients with an allergy to ultrasound transducer gel or measuring tape

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TKA Patients<br> | Other: Measurements Using Ultrasound<br>* Ultrasound measurements will be made in 5 positions. The ultrasound probe will be measuring from a fixed external location of the thigh. The 5 positions include: external rotation, neutral, manual tissue external rotation, straight leg raise at 30 degrees and hip/knee flexion at 90 degrees.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Skin to Adductor Canal Distance Disparity | The largest distance disparity as measured from the 5 different leg positions | Measurements will be made on the day of surgery, no other assessment or follow up needed | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Total Knee Arthroplasty, Adductor Canal Block
Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

Study Overview
=================
Brief Summary
-----------------
Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death. Although angiotensin receptor blockers (ARBs) are effective for patients with diabetes and chronic kidney disease in reducing or preventing cardiovascular diseases, there has been no decisive study that demonstrated treatment with ARBs is effective in patients on HD.

Conditions
-----------------
Cardiovascular Disease

Intervention / Treatment
-----------------
* Drug: candesartan or valsartan or losartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 30 to 80 years of age Receiving hemodialysis at least 12 months and less than 5 years Pre-dialysis systolic blood pressure was more than 160 mmHg, or more than 150 mmHg if the patients received antihypertensive agents. Exclusion Criteria: Use of angiotensin receptor blocker or angiotensin converting enzyme inhibitor

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: candesartan or valsartan or losartan|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hemodialysis
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Study Overview
=================
Brief Summary
-----------------
Study of the efficacy and safety of aliskiren when added to losartan and optimal antihypertensive therapy in patients with hypertension, type 2 diabetes, and kidney disorders to monitor improvement in any of these conditions.

Official Title
-----------------
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Conditions
-----------------
Diabetic Nephropathy

Intervention / Treatment
-----------------
* Drug: aliskiren


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hypertension Elevated urinary protein levels Confirmed type 2 diabetes Exclusion Criteria: Certain diseases Uncontrolled diabetes Type 1 diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: aliskiren|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in urinary albumin creatinine ratio after 24 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Equal/more than 50% reduction from baseline in urinary albumin creatinine ratio after 24 weeks |  |  | 
| Change from baseline in urinary albumin excretion rate after 24 weeks |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes, nephropathy, hypertension, aliskiren, losartan